$NTRA

Fesko John sold $79K of NTRA

Fesko John (PRESIDENT, CHIEF BUS. OFFICER) sold 295 shares of Natera, Inc. (NTRA) at $267.99 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fesko John
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates insider trading records but does not introduce new company fundamentals.

02

Market read

Traders may note the insider sale for sentiment, but there is no new guidance, contract, or regulatory event to drive repricing.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, and 10b5-1 sales are often scheduled for liquidity rather than signaling.

Relevance 2/10Novelty 2/10Timing: Filed 2026-08-05, transaction dated 2026-08-03.

Background

The article is a primary-source SEC Form 4 insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera Form 4 shows officer Fesko John sold 295 shares on 2026-08-03 for about $79,056 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is an open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, and the article contains no new guidance, deal, or regulatory development.

Market effects

No disclosed sector-level signal; this is company-specific insider transaction reporting.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can be interpreted as a lack of near-term upside conviction by some traders.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Fesko John

    President and Chief Business Officer who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAHigh

Why Natera (NTRA) Stock Is Up Today

Natera (NTRA) stock rose 2.2% after the FDA granted Breakthrough Device designation to its multi-cancer early detection assay. The assay showed promising performance data across 12 cancer types. The company's shares are up 74.9% year-to-date, trading near a 52-week high of $425.64. Natera plans a commercial launch in Japan in 2027 for its Signatera test, approved as a companion diagnostic for bladder cancer.

$NTRAHigh

Natera Receives FDA Breakthrough Device Designation for Multi-Cancer Early Detection Blood Test

Natera (NTRA) received FDA Breakthrough Device Designation for its multi-cancer early detection blood test, based on clinical data covering 12 cancer types. The designation accelerates regulatory review but does not guarantee approval. The test analyzes cell-free DNA to detect cancer signals and their likely origin. Natera aims to expand early cancer detection options, though clinical performance and benefits require further evaluation.